Steven H Holtzman
CIK 1300247 · EVP Corporate Development · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.35M
Companies
4
Total Filings
48
Lifetime Open-Market Net
-$7.36M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CAMP | Director | 108,946 | $4.65 | $506.6K | $0 | 3 | 2026-06-12 |
| BIIB | EVP Corporate Development | 8,326 | $221.56 | $1.84M | -$4.22M | 24 | 2016-02-25 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Director | 3,945 | $0.04 | $176 | -$3.14M | 15 | 2012-06-04 |
| ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Director | — | — | — | $0 | 6 | 2010-05-28 |
Recent Filings · Page 3 of 5
48 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-09-18 | BIIB | Sell (S) | −3,501 | -$836.7K | EDGAR |
| 2013-02-14 | BIIB | Grant (A) | — | $0 | EDGAR |
| 2013-02-12 | BIIB | Mixed | +1,404 | -$154.6K | EDGAR |
| 2013-02-05 | BIIB | Mixed | +3,481 | -$263.9K | EDGAR |
| 2012-06-04 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Sell (S) | −57,573 | -$749.0K | EDGAR |
| 2012-05-31 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Mixed | −215,261 | -$2.60M | EDGAR |
| 2012-05-18 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-02-10 | BIIB | Grant (A) | — | $0 | EDGAR |
| 2012-02-03 | BIIB | Mixed | +3,501 | -$201.0K | EDGAR |
| 2011-05-19 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.